ADC Therapeutics (ADCT) EPS (Basic) (2020 - 2026)
ADC Therapeutics (ADCT) posted quarterly EPS (Basic) of -$0.21 for Q1 2026, up 40.6% year-on-year from -$0.15 in Q1 2025, and up 28.76% on a QoQ basis from -$0.3 in Q3 2025.
ADC Therapeutics (ADCT) EPS (Basic) (2020 - 2026) Analysis & Trends
ADC Therapeutics (ADCT) has reported EPS (Basic) for 7 consecutive years, with -$0.21 the latest figure, recorded in Q1 2026.
- Quarterly EPS (Basic) rose 40.6% year-over-year to -$0.21 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$0.85 (up 23.21% YoY) and the FY2022 annual result came in at -$1.95, up 35.03% from the prior year.
- EPS (Basic) climbed to -$0.21 in Q1 2026 per ADCT's latest filing, from -$0.3 in the prior quarter.
- Over the last five years, EPS (Basic) for ADCT reached as high as -$0.21 in Q1 2026 and fell as low as -$0.84 in Q2 2022.
- A 5-year average of -$0.47 and a median of -$0.46 in 2024 frame the typical range for EPS (Basic).
- Annual changes were most pronounced in 2022 — EPS (Basic) soared 67.71% — and 2023, when it sank 239.09%.
- Year by year, EPS (Basic) stood at -$0.23 in 2022, then slumped by 137.11% to -$0.55 in 2023, then advanced by 24.29% to -$0.42 in 2024, then rose by 28.0% to -$0.3 in 2025, then gained by 28.76% to -$0.21 in 2026.
- According to Business Quant data, EPS (Basic) over the past three periods registered -$0.21, -$0.3, and -$0.5 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | 0.00 |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | 0.00 |
| 4 | BeOne Medicines | 471.62 Bn | 466.83 Bn | 1.35 Bn | 0.16 |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 4.06 |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | 6.99 |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | 0.00 |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn | 7.59 |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 1.55 |
| 10 | ADC Therapeutics | 175.72 Mn | -55.29 Mn | 17.38 Mn | -0.21 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.21 |
| Sep 30, 2025 | -0.30 |
| Jun 30, 2025 | -0.50 |
| Mar 31, 2025 | -0.36 |
| Sep 30, 2024 | -0.42 |
| Jun 30, 2024 | -0.38 |
| Mar 31, 2024 | -0.56 |
| Sep 30, 2023 | -0.55 |
| Jun 30, 2023 | -0.59 |
| Mar 31, 2023 | -0.74 |
| Dec 31, 2022 | -0.23 |
| Sep 30, 2022 | -0.65 |
| Jun 30, 2022 | -0.84 |
| Mar 31, 2022 | -0.22 |
| Dec 31, 2021 | -0.46 |
| Sep 30, 2021 | -0.93 |
| Jun 30, 2021 | -0.95 |
| Mar 31, 2021 | -0.67 |
| Dec 31, 2020 | -0.86 |
| Sep 30, 2020 | -0.29 |